

## ENSAYOS CLÍNICOS TUMORES GENITOURINARIO

### - UROTELIO/VEJIGA

#### **MK3475-676**

*“Ensayo de fase 3 de BCG con o sin pembrolizumab para el cáncer de vejiga sin invasión muscular de alto riesgo (KEYNOTE-676)”*

<https://clinicaltrials.gov/ct2/show/NCT03711032?term=MK3475-676&rank=1>

#### **MS100070 0119**

*A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress with First Line Platinum-Containing Chemotherapy*

[https://clinicaltrials.gov/ct2/show/NCT05327530?term=MS100070\\_0119&draw=2&rank=1](https://clinicaltrials.gov/ct2/show/NCT05327530?term=MS100070_0119&draw=2&rank=1)

### - C.RENAL

#### **MK6482-011**

*An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti- PD-1/L1 Therapy*

<https://clinicaltrials.gov/ct2/show/NCT04586231?term=MK6482-011&draw=2&rank=1>

### - CA.PRÓSTATA

#### **D361BC00001 (CAPitello-281)**

*“Ensayo clínico fase III, doble ciego, aleatorizado, controlado con placebo que evalúa la eficacia y la seguridad de Capivasertib + Abiraterona versus Placebo + Abiraterona, como tratamiento para pacientes con Cáncer de próstata metastásico de novo, sensible a hormonas (mCPHS) caracterizado por la deficiencia de PTEN (CAPitello-281).”*

[https://clinicaltrials.gov/ct2/results?cond=Prostate+Cancer&term=capitello&type=&rslt=&age\\_v=&qndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&rsb=&strd\\_s=&strd\\_e=&prcd\\_s=&prcd\\_e=&sfpd\\_s=&sfpd\\_e=&rfpd\\_s=&rfpd\\_e=&lupd\\_s=&lupd\\_e=&sort=](https://clinicaltrials.gov/ct2/results?cond=Prostate+Cancer&term=capitello&type=&rslt=&age_v=&qndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&rsb=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=)

#### **MK3475-365**

*“Ensayo de fase Ib/II de tratamientos combinados con pembrolizumab (MK-3475) en el cáncer de próstata resistente a la castración metastásico (CPRCm) (KEYNOTE-365) “*

<https://clinicaltrials.gov/ct2/show/NCT02861573?term=MK3475-365&rank=1>

- CA.OVARIO

**FLORA-5(fase III)**

*A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma*

<https://clinicaltrials.gov/ct2/show/NCT04498117?term=FLORA-5&draw=2&rank=1>

**ART0380C001(fase I/IIa)**

*A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors*

<https://clinicaltrials.gov/ct2/show/NCT04657068?term=ART0380&draw=2&rank=1>